Stifel analyst David Grossman lowered the firm’s price target on DarioHealth (DRIO) to $2 from $3.50 and keeps a Buy rating on the shares. The firm reduced its 2025 estimates to reflect a more back-end weighted year with its 2025 revenue forecast of $32M reflecting a pace slightly above the Q4 run-rate, the analyst tells investors in a post-earnings note. While DarioHealth is smaller than many competitors, the firm is “encouraged” by ongoing efforts to create a comprehensive digital health solution, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth Reports Strong Revenue Growth in 2024
- DarioHealth’s Balanced Outlook: Promising Growth Amidst Uncertainties Justifies Hold Rating
- Morning Movers: Redfin soars and Rocket Companies dips following deal
- DarioHealth reports Q4 revenue $7.6M, consensus $7.39M
- DRIO Upcoming Earnings Report: What to Expect?
Questions or Comments about the article? Write to editor@tipranks.com